Artificial lipids stabilized camptothecin incorporated in liposomes

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 5, 2008, Pages 990-993

  Maitani, Yoshie ^a   Katayama, Sayaka ^a   Kawano, Kumi ^a   Hayama, Akihiro ^a   Toma, Kazunori ^b  

^a HOSHI UNIVERSITY   (Japan)

^b NOGUCHI INSTITUTE   (Japan)

Author keywords

Artificial lipid; Camptothecin; Incorporation efficiency; Incorporation stability; Liposome; Release test

Indexed keywords

3,4,5 TRIS(DODECYLOXY)BENZOIC ACID; 3,5 BIS(DODECYLOXY)BENZOIC ACID; 4 N DODECYLOXY BENZOIC ACID; BENZOIC ACID DERIVATIVE; CAMPTOTHECIN; CHOLESTEROL; LACTONE; LIPID; LIPOSOME; OLEIC ACID; PHENYL GROUP; PHOSPHATIDYLCHOLINE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FLUORESCENCE; FLUORESCENCE POLARIZATION; HYDROGENATION; LIPID BILAYER; SOYBEAN; STEADY STATE;

ALGORITHMS; ANISOTROPY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG CARRIERS; EXCIPIENTS; FLUORESCENCE POLARIZATION IMMUNOASSAY; LIPIDS; LIPOSOMES;

EID: 44349104727     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.990     Document Type: Article

References (20)

1. Wall M. E., Wani M. C., Cook C. E., Palmer K. H., Mcphail A. T., Sim G. A., J. Am. Chem. Soc., 88, 3888-3890 (1966).
2. Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M., Science, 246, 1046-1048 (1989).
3. Giovanella B. C., Hinz H. R., Kozielski A. J., Stehlin J. S., Silber R., Potmesil M., Cancer Res., 51, 3052-3055 (1991).
4. Hertzberg R. P., Caranfa M. J., Hecht S. M., Biochemistry, 28, 4629-4638 (1989).
5. Fassberg J., Stella V. J., J. Pharm. Sci., 81, 676-684 (1992).
6. Conover C. D., Greenwald R. B., Pendri A., Gilbert C. W., Shum K. L., Cancer Chemother. Pharmacol., 42, 407-414 (1998).
7. Fleming A. B., Haverstick K., Saltzman W. M., Bioconjug. Chem., 15, 1364-1375 (2004).
8. Mi Z., Burke T. G., Biochemistry, 33, 10325-10326 (1994).
9. Warnecke A., Kratz F., Bioconjug. Chem., 14, 377-387 (2003).
10. Akimoto K., Kawai A., Ohya K., Chem. Pharm. Bull., 42, 2135-2138 (1994).
11. Daoud S. S., Fetouh M. I., Giovanella B. C., Anticancer Drugs, 6, 83-93 (1995).
12. Cortesi R., Esposito E., Maietti A., Menegatti E., Nastruzzi C., Int. J. Pharm., 159, 95-103 (1997).
13. Shenderova A., Burke T. G., Schwendeman S. P., Pharm. Res., 16, 241-248 (1997).
14. Tong W., Wang L., D'souza M. J., Drug Dev. Ind. Pharm., 29, 745-756 (2003).
15. Kang J., Kumar V., Yang D., Chowdhury P. R., Hohl R. J., Eur. J. Pharm. Sci., 15, 163-170 (2002).
16. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., Maitani Y., J. Controlled Release, 112, 329-332 (2006).
17. Opanasopit P., Yokoyama M., Watanabe M., Kawano K., Maitani Y., Okano T., Pharm. Res., 21, 2001-2008 (2004).
18. Watanabe M., Kawano K., Yokoyama M., Opanasopit P., Okano T., Maitani Y., Int. J. Pharm., 308, 183-189 (2006).
19. Watanabe M., Kawano K., Toma K., Hattori Y., Maitani Y., J. Controlled Release, in press.
20. Hara M., Takanashi Y., Tuzuki N., Kawakami H., Toma K., Higuchi A., Cytotechnology, 42, 13-20 (2003).